Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Treatment for B-cell malignancies like lymphoma and chronic lymphocytic leukemia (CLL) is shifting towards targeted therapies.
• Immunotherapeutic modalities including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy are key players.
• These therapies commonly target B-cell-associated antigens such as CD19, CD20, CD22, and CD79b.

Purpose of the Study:

• To review the evolving landscape of immunotherapeutic strategies for B-cell lymphomas and CLL.
• To highlight the mechanisms and efficacy of various targeted agents, including T-cell engagers (TCEs) and antibody-drug conjugates (ADCs).
• To assess the potential of immunotherapy, alone or in combination, to supplant conventional chemotherapy in first-line treatment.

Main Methods:

• Review of current immunotherapeutic approaches in B-cell malignancies.
• Analysis of clinical trial data for TCEs (anti-CD20xCD3, anti-CD19xCD3) and ADCs targeting B-cell antigens.
• Evaluation of combination strategies involving immunotherapy, mAbs, chemoimmunotherapy, and immune checkpoint inhibitors.

Main Results:

• Anti-CD20xCD3 TCEs show promising efficacy in various lymphoma subtypes, particularly indolent forms.
• Anti-CD19xCD3 TCEs are under development, with blinatumomab showing less impressive results compared to anti-CD19 CAR-T cell therapy.
• ADCs targeting CD30, CD79b, or CD19 demonstrate effectiveness when combined with other treatments.

Conclusions:

• Immunotherapy represents a significant advancement in treating B-cell lymphomas and CLL.
• TCEs and ADCs are emerging as potent therapeutic options, with ongoing research into their optimal application.
• Further studies are needed to determine if immunotherapy can replace chemotherapy as a first-line treatment option.